Trial Profile
A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs LAM 003 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors AI Therapeutics; OrphAI Therapeutics
- 17 Dec 2021 Status changed from recruiting to completed.
- 09 Feb 2018 New trial record